20231
ORBO™ 24 2-HMP on Amberlite™ XAD®-2 (20/40), 150/75 mg
W,W,W separators, O.D. × L 6 mm × 105 mm, pkg of 25 ea
Synonym(s):
ORBO™ 2-HMP on Supelpak™ 20N Tube
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
47131900
NACRES:
NB.21
material
W,W,W separators
Quality Level
agency
EPA TO-15, OSHA 52,61
product line
Amberlite™, ORBO™
composition
Bed A, 150 mg , Bed B, 75 mg
packaging
pkg of 25 ea
manufacturer/tradename
ORBO™ 24
technique(s)
active air sampling: suitable
O.D. × L
6 mm × 105 mm
matrix
XAD-2 2-(Hydroxymethyl)piperidine (2-HMP) on XAD-2
particle size
20-40 mesh
application(s)
air monitoring
environmental
industrial hygiene
storage temp.
2-8°C
Legal Information
Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
Supelpak is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow
signalword
Danger
hcodes
Hazard Classifications
Eye Dam. 1 - Skin Corr. 1B
Storage Class
8A - Combustible corrosive hazardous materials
wgk
WGK 3
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
F J Egea González et al.
Journal of AOAC International, 80(5), 1091-1097 (1997-11-05)
A method to sample and analyze chlorothalonil and dichlofluanid in greenhouse air was evaluated. Analysis was performed by gas chromatography with electron capture detection and gas chromatography-mass spectrometry. Solid sorbents such as Chromosorb 102, Porapak R, Supelpak-2, Amberlite XAD-2, Amberlite
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.